GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: example 10 [US10676465] [2] | PF-07081532 | PF07081532
Compound class:
Synthetic organic
Comment: Lotiglipron (PF-07081532) is an oral, small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist [3]. It was developed for potential to treat type 2 diabetes and obesity.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Development of lotiglipron (PF-07081532) was discontinued (in phase 2) in late 2023 following detection of elevated transaminase (indicative of liver injury) in trial participants [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05158244 | Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Phase 1 Interventional | Pfizer | 3 | |
NCT04305587 | Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Phase 1 Interventional | Pfizer | 3 | |
NCT05579977 | Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity | Phase 2 Interventional | Pfizer | 1 |